
Keywords: AE; adverse event; FCM; ferric carboxymaltose; FG; ferric gluconate; ID; iron dextran; IM; intramuscular; IS; iron sucrose; IV; intravenous; NNH; number needed to harm; NNP; number needed to prevent; RD; risk difference; REM; random-effects model; RR; rel